ArticleDiscover oncology2026
Construction and validation of a novel prognostic signature that correlates with immune infiltration based on glycolysis related lncRNAs in osteosarcoma.
Article in Discover oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
backgroundOsteosarcoma is the most frequent malignancy for adolescents in bone system, which has caused huge disease burdens for both patients and society. Aberrant activation of glycolysis has been proven to promote osteosarcoma progression. But the prognostic roles of glycolysis-related lncRNAs still remain obscure. We aim to establish a glycolysis-related lncRNA-based signature to predict the prognosis of osteosarcoma.
methodsGlycolysis-related genes were retrieved from GSEA website. Differentially expressed genes between osteosarcoma samples and the normal samples were determined in GSE36001. Glycolysis-related lncRNA were identified by correlation analysis. The prognosis model was constructed by Cox regression analysis and LASSO analysis. Independent prognostic factors of osteosarcoma were determined by multivariate Cox regression analysis. A prognostic nomogram was further developed with estimation of ROC curves, calibration curves and DCA curves. GO and KEGG enrichment analyses and immune infiltration analyses (ssGSEA, xCELL and CIBERSORT) were conducted to characterize intrinsic features of risk group.
resultsA 11-glycolysis-related lncRNA prognosis model was constructed and validated in validation cohort and several clinical subgroups. ROC curve results showed that the AUC values of training set and validation set were 0.935 and 0.750. Risk score and metastasis status were identified as independent prognostic factors whereby the nomogram was built on them. The robust discriminability of the nomogram was verified. Functional and immunological characterization identified that some cancer-related signaling pathways and mutiple immune infiltrating cells are significantly associated with the signature.
conclusionsThis study revealed the prognostic value of glycolytic-associated lncRNAs in osteosarcoma. The novel glycolysis-associated lncRNA-based model may offer new insights into prognostic evaluation and clinical risk decision for patients with osteosarcoma.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.